In contrast, increased kallistatin levels in serum may promote DN progression by inhibiting tissue kallikrein activity, thereby attenuating the protection of kallikrein-kinin system and inducing renin-angiotensin system (RAS) overactivation (76). The gene discussed is KLK4; the disease is liver dysplastic nodule.